

Version of Amended Claims With Markings t Show Changes Made:

4. (Amended) An isolated nucleic acid molecule consisting of a nucleotide sequence selected from the group consisting of:

(a) a nucleotide sequence that encodes a protein comprising the amino acid sequence of [shown in] SEQ ID NO:[3, 6, 9, . . . 1527, 1530 and 1533]855;

[(b) a nucleotide sequence that encodes of an allelic variant of the amino acid sequence shown in SEQ ID NO:3, 6, 9, . . . 1527, 1530 and 1533, wherein said nucleotide molecule hybridizes to the nucleic acid molecule shown in genomic sequences SEQ ID NO:1, 4, 7, . . . 1525, 1528 and 1531, or transcript sequences SEQ ID NO:2, 5, 8, . . . 1526, 1529 and 1532, under stringent conditions;

(c) a nucleotide sequence that encodes an ortholog of an amino acid sequence shown in SEQ ID NO:3, 6, 9, . . . 1527, 1530 and 1533, wherein said nucleic acid molecule hybridizes to the nucleic acid molecule shown in genomic sequences SEQ ID NO:1, 4, 7, . . . 1525, 1528 and 1531, or transcript sequences SEQ ID NO:2, 5, 8, . . . 1526, 1529 and 1532, under stringent condition;

(d) a nucleotide sequence that encodes a fragment of the amino acid sequence shown in SEQ ID NO:3, 6, 9, . . . 1527, 1530 and 1533, wherein said the fragment comprises at least 10 contiguous amino acids; and]

(b) a nucleic acid molecule consisting of the nucleic acid sequence of SEQ ID NO:854;

(c) a nucleic acid molecule consisting of the nucleic acid sequence of SEQ ID NO:853; and

(d) [(e)] a nucleic acid molecule that is [the complement of] completely complementary to a nucleotide molecule of (a)-[(d)](c).

15. (Amended) A method for detecting the presence of a nucleic acid [sequence] molecule of claim 4 in a sample, the method comprising contacting the sample with an oligonucleotide comprising at least 20 contiguous

Serial No. 09/619,049

nucleotides that hybridizes to the nucleic acid [sequences] molecule under stringent conditions, wherein the stringent condition is hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50-65°C, and

determining whether the oligonucleotide binds to the nucleic acid [sequence] molecule in the sample.

Serial No. 09/619,049

REMARKS


By way of the above amendments, claims 1-3, 5, 7, 9-14, and 16-20 have been canceled as being redundant or being directed to non-elected subject matter; claims 4 and 15 have been amended; and claims 21-26 have been added. As such, claims 4, 6, 8, 15 and 21-26 are presently pending.

Support for the amendments to the claims and the newly added claims can be found at least in the old claims, the specification, and in Figure Sheets 1-836. The amendments to the claims and the newly added claims add no new subject matter and their entry is respectfully requested.

Applicants respectfully assert that the claims are in condition for examination on the merits.

Respectfully submitted,

CELERA GENOMICS

By: 
Justin D. Karjala
Reg. No. 43,704

Date: September 19, 2001

Celera Genomics Corporation
45 West Gude Drive, C2-4#20
Rockville, MD 20850
Tel: 240-453-3812
Fax: 240-453-3084